StarShot music
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
Illuminet Creative Blog
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
AbbVie’s Skyrizi gains pediatric psoriatic disease indication
kmk-vova/iStock via Getty Images The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize...
